The companies are developing and commercializing MPC-06-ID, a phase 3 allogeneic cell therapy candidate. The companies hope the therapy can treat chronic lower back pain caused by degenerative disc disease. If successful, Grünenthal will have commercialization rights to the drug in Europe and Latin America.
More articles on biologics:
Stryker adds to spine division with $550M acquisition: 3 details
New York spine surgeon pleads guilty to illegal painkiller prescription, faces $250K fine
15 spine, neurosurgeon moves in August
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
